Browse DGKG

Summary
SymbolDGKG
Namediacylglycerol kinase, gamma 90kDa
Aliases DAGK3; diacylglycerol kinase, gamma (90kD); DGK-GAMMA; DAG kinase gamma; diacylglyerol kinase gamma; diglyce ......
Chromosomal Location3q27-q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Membrane. Note=Can be loosely bound to the membranes.
Domain PF00130 Phorbol esters/diacylglycerol binding domain (C1 domain)
PF14513 Diacylglycerol kinase N-terminus
PF00609 Diacylglycerol kinase accessory domain
PF00781 Diacylglycerol kinase catalytic domain
Function

Reverses the normal flow of glycerolipid biosynthesis by phosphorylating diacylglycerol back to phosphatidic acid.

> Gene Ontology
 
Biological Process GO:0007205 protein kinase C-activating G-protein coupled receptor signaling pathway
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0030168 platelet activation
GO:0030258 lipid modification
GO:0046486 glycerolipid metabolic process
GO:0046834 lipid phosphorylation
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
Molecular Function GO:0004143 diacylglycerol kinase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04070 Phosphatidylinositol signaling system
hsa00561 Glycerolipid metabolism
hsa00564 Glycerophospholipid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-114508: Effects of PIP2 hydrolysis
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolDGKG
Namediacylglycerol kinase, gamma 90kDa
Aliases DAGK3; diacylglycerol kinase, gamma (90kD); DGK-GAMMA; DAG kinase gamma; diacylglyerol kinase gamma; diglyce ......
Chromosomal Location3q27-q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DGKG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolDGKG
Namediacylglycerol kinase, gamma 90kDa
Aliases DAGK3; diacylglycerol kinase, gamma (90kD); DGK-GAMMA; DAG kinase gamma; diacylglyerol kinase gamma; diglyce ......
Chromosomal Location3q27-q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DGKG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDGKG
Namediacylglycerol kinase, gamma 90kDa
Aliases DAGK3; diacylglycerol kinase, gamma (90kD); DGK-GAMMA; DAG kinase gamma; diacylglyerol kinase gamma; diglyce ......
Chromosomal Location3q27-q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DGKG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0990.752
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8670.157
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7990.0799
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8760.0436
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9430.623
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7970.726
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2570.531
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4930.546
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0230.98
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8980.327
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4620.233
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.230.177
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DGKG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.811.8120.427
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862516.78.31
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.19.1140.596
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.3033.30.0365
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDGKG
Namediacylglycerol kinase, gamma 90kDa
Aliases DAGK3; diacylglycerol kinase, gamma (90kD); DGK-GAMMA; DAG kinase gamma; diacylglyerol kinase gamma; diglyce ......
Chromosomal Location3q27-q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DGKG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDGKG
Namediacylglycerol kinase, gamma 90kDa
Aliases DAGK3; diacylglycerol kinase, gamma (90kD); DGK-GAMMA; DAG kinase gamma; diacylglyerol kinase gamma; diglyce ......
Chromosomal Location3q27-q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DGKG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DGKG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDGKG
Namediacylglycerol kinase, gamma 90kDa
Aliases DAGK3; diacylglycerol kinase, gamma (90kD); DGK-GAMMA; DAG kinase gamma; diacylglyerol kinase gamma; diglyce ......
Chromosomal Location3q27-q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DGKG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDGKG
Namediacylglycerol kinase, gamma 90kDa
Aliases DAGK3; diacylglycerol kinase, gamma (90kD); DGK-GAMMA; DAG kinase gamma; diacylglyerol kinase gamma; diglyce ......
Chromosomal Location3q27-q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DGKG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDGKG
Namediacylglycerol kinase, gamma 90kDa
Aliases DAGK3; diacylglycerol kinase, gamma (90kD); DGK-GAMMA; DAG kinase gamma; diacylglyerol kinase gamma; diglyce ......
Chromosomal Location3q27-q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DGKG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDGKG
Namediacylglycerol kinase, gamma 90kDa
Aliases DAGK3; diacylglycerol kinase, gamma (90kD); DGK-GAMMA; DAG kinase gamma; diacylglyerol kinase gamma; diglyce ......
Chromosomal Location3q27-q28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DGKG collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting DGKG.
ID Name Drug Type Targets #Targets
DB00144Phosphatidyl serineSmall MoleculeATP8A1, DGKD, DGKG, PISD, PRKCA, PTDSS1, PTDSS2, SCARB1, SMPD3, SM ......10